Yann Dean is an advisor to the Medicxi investment team with experience in designing, managing and raising capital for clinical drug development projects out of academia. During his career, Yann has taken ten therapeutic monoclonal antibodies from discovery phase into clinical development and, to date, five of these molecules have secured licensing deals with major pharmaceutical companies.
Prior to Medicxi, Yann held various roles at NovImmune, a Geneva-based biotech, including head of the department of experimental biology and pharmacology. He has founded or co-founded a number of companies and headed the Eclosion Foundation, a life-sciences incubator in Geneva and xSeedD, a biotech company supporting early drug discovery programs.
Yann has a PhD from the University of Wales, College of Medicine and completed post-doctorate studies at the Serono Pharmaceutical Research Institute. He has published several peer-reviewed scientific articles and is an inventor on multiple patents related to the validation of therapeutic targets and development of biological drugs.